戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ociated mutations infrequently emerged after high-dose therapy.
2 osensitive relapse are better candidates for high-dose therapy.
3 onse to the regimen given immediately before high-dose therapy.
4 chieved a partial response before undergoing high-dose therapy.
5 of 61 months (range, 40 to 139 months) after high-dose therapy.
6  at risk for early toxic mortality following high-dose therapy.
7  x 10(5)/kg GM-CFC; 22 patients proceeded to high-dose therapy.
8 drug-tolerant cells is related to the use of high-dose therapy.
9 transplant into high-risk patients following high-dose therapy.
10 ies failed to show a definitive advantage to high-dose therapy.
11 ion-free survival and overall survival after high-dose therapy.
12 lenalidomide predicts a poorer outcome after high-dose therapy.
13 rticularly suited for older adults requiring high-dose therapy.
14 ing problem that occurs not only in those on high-dose therapy.
15 mor effects independent of the action of the high-dose therapy.
16 n unequivocal benefit for consolidation with high-dose therapy.
17 eligible for the triple-tandem consolidation high-dose therapy.
18 ration and treatment with either low-dose or high-dose therapy.
19 s largely incurable despite conventional and high-dose therapies.
20 nts who were in or near CR before undergoing high-dose therapy, 14 remain continuously progression-fr
21 ation (59%) led to an improved CR rate after high-dose therapy (41.2% vs 20.0%; P = .02), translating
22 andard practice of administering aggressive, high-dose therapies and motivate further experimental an
23          169 (79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients on low-d
24 successfully treated with the combination of high-dose therapy and AHSCT, confirming the efficacy of
25 onventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant
26                   These results suggest that high-dose therapy and ASCT during first remission may im
27                               The results of high-dose therapy and ASCT for patients with relapsed di
28                                              High-dose therapy and ASCT is an effective treatment str
29                                 Responses to high-dose therapy and ASCT were complete response (30%),
30     A prospective randomized study comparing high-dose therapy and ASCT with conventional chemotherap
31 tion/maintenance protocol (CC) or to receive high-dose therapy and ASCT.
32 arabinoside, and platinum (DHAP) followed by high-dose therapy and auto-SCT or myeloablative conditio
33          Our results confirm the efficacy of high-dose therapy and autografting in recurrent or refra
34 atched patients demonstrate an advantage for high-dose therapy and autografting in the sustained cont
35 come ultimate determinants of the success of high-dose therapy and autografting.
36 colony-stimulating factor (GM-CSF) following high-dose therapy and autologous bone marrow transplant
37 ted a pilot study to investigate the role of high-dose therapy and autologous bone marrow/stem cell t
38 lle 3) after two or four cycles proceeded to high-dose therapy and autologous hematopoietic cell tran
39  failure-free survival is possible following high-dose therapy and autologous hematopoietic rescue fo
40 ble patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with i
41 hes both in older patients, not eligible for high-dose therapy and autologous stem cell transplantati
42 r without etoposide (CHOEP), consolidated by high-dose therapy and autologous stem cell transplantati
43 tezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantati
44 ively treated by R-ICE or R-DHAP followed by high-dose therapy and autologous stem cell transplantati
45  with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantati
46                                              High-dose therapy and autologous stem cell transplantati
47 mide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantati
48 y to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantati
49 linical trials established the importance of high-dose therapy and autologous stem-cell rescue and hi
50  lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.
51 of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (H
52      Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantati
53                                 The role for high-dose therapy and autologous stem-cell transplantati
54  (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantati
55 t they are often denied potentially curative high-dose therapy and autologous stem-cell transplantati
56 e, one to five); six patients relapsed after high-dose therapy and autologous stem-cell transplantati
57 ith either conventional-dose chemotherapy or high-dose therapy and autologous stem-cell transplantati
58 is uncertain whether cures are possible with high-dose therapy and bone marrow transplant from a huma
59 ersistence of minimal residual disease after high-dose therapy and either allogeneic or autologous st
60 nd normal cytogenetics, who received uniform high-dose therapy and found FLT3 ITD in 23 (28%) patient
61  MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transpl
62 ts were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue,
63                                 Outcome from high-dose therapy and significant prognostic factors wer
64           Seventy of these patients received high-dose therapy and stem-cell transplantation in first
65 ly diagnosed patients who went on to receive high-dose therapy and tandem stem cell transplants.
66 ake strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is fe
67 he rationale, methods, and recent results of high-dose therapy and the questions that it raises.
68                Stratification by low-dose or high-dose therapy and the use of concurrent aspirin was
69 tes are much higher for patients who receive high-dose therapy and transplantation.
70 89 high-risk breast cancer patients received high-dose therapy and were randomized to receive an auto
71 in which immunochemotherapy, with or without high-dose therapy, and autologous stem cell transplantat
72 tins in CABG patients, including the role of high-dose therapy, and highlight areas for future study.
73 relapsed disease have improved survival with high-dose therapy, and those with high-risk disease may
74 -day cycles for 2 years following induction, high-dose therapy, and transplantation.
75 uximab and high-dose cytarabine, followed by high-dose therapy appears quite promising.
76                   Further development of new high-dose therapy approaches has led to a reduction in t
77 ions remain in terms of the proper timing of high-dose therapy, appropriate stratification by risk fa
78  outcomes, and increased nephrotoxicity with high-dose therapy are challenging its current role as fi
79                                   The use of high-dose therapy at relapse, a longer duration of remis
80 , doxorubicin, vincristine, and prednisone + high-dose therapy/autologous stem cell rescue), RHCVAD+H
81  achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (
82                         The incorporation of high-dose therapy/autologous stem cell transplantation (
83 of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 200
84 g within 1 year benefited significantly from high-dose therapy by all outcome measures (OS, EFS, FFP)
85         This effect has been emphasized over high-dose therapy by using less intensive, and therefore
86 sing 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hemato
87 ears follow-up favored patients who received high-dose therapy compared with conventional salvage tre
88                                              High-dose therapy consisted of fractionated total-body i
89 Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation.
90                         The controversy over high-dose therapy continues, and its role in the managem
91 onors underwent an allograft as their second high-dose therapy cycle.
92       It has become clear, however, that the high dose therapy does not eradicate the malignancy in m
93                                 Nonetheless, high-dose therapy does appear feasible and may offer cur
94                             We conclude that high-dose therapy followed by allo-SCT from related or u
95          This study evaluated the results of high-dose therapy followed by autologous bone marrow or
96 r refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic p
97                                              High-dose therapy followed by autologous stem-cell trans
98  patients with multiple myeloma treated with high-dose therapy followed by hematopoietic stem cell tr
99                             We conclude that high-dose therapy followed by transplantation from a HLA
100 e a more significant advance in the field of high-dose therapy for multiple sclerosis.
101                       When incorporated into high-dose therapy for myeloma, thalidomide increased the
102 er studies are helping to define the role of high-dose therapy for patients with Hodgkin's lymphoma,
103                      Before consideration of high-dose therapy for recurrent/persistent advanced ovar
104                                              High-dose therapy (> 145 mcg daily) was effective in 11
105                However, neither low-dose nor high-dose therapy had an effect on insulin-mediated supp
106 isease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5
107                                              High-dose therapy has been used in progressive multiple
108 lopment and application of immunotherapy and high-dose therapy have demonstrated high response rates
109  of novel therapies and the increased use of high-dose therapy have translated into better outcome fo
110      A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow trans
111 we evaluated its efficacy and toxicity after high-dose therapy (HDT) and autologous hematopoietic cel
112 ) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transpl
113                                              High-dose therapy (HDT) and autologous stem-cell transpl
114 that autologous hematopoietic cell-supported high-dose therapy (HDT) effected higher complete respons
115                                              High-dose therapy (HDT) has increased complete remission
116 vide superior outcome to standard treatment, high-dose therapy (HDT) has usually been limited to pati
117  (ESFT) is poor, and the relative benefit of high-dose therapy (HDT) is controversial.
118 ith malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial.
119 oietic colony-stimulating factors (CSFs), or high-dose therapy (HDT) with autologous bone marrow supp
120  progression, achieved response criteria for high-dose therapy (HDT), and had no resection before ind
121 or MM restaging in 3,077 patients undergoing high-dose therapy (HDT).
122 th metastatic NB had favorable outcomes with high-dose therapy if their tumors were hyperdiploid and
123 rther elucidate the role of radiotherapy and high-dose therapy in Hodgkin's disease and the non-Hodgk
124 ingle institution comparing conventional and high-dose therapy in matched patients demonstrate an adv
125        Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-
126 f PCR-detectable MRD after BMT suggests that high-dose therapy may contribute to improved outcome in
127                                              High-dose therapy may eventually become the standard for
128 ic outcomes, such as dosimetric estimations, high-dose therapies, multiple fractionated administratio
129                             Future trials of high-dose therapy must define rigorous eligibility crite
130                 Despite an increasing use of high-dose therapy of i.v. gammaglobulin (IVIg) in the tr
131                                              High-dose therapy of imatinib was beneficial for patient
132 n 1 x 10(6)/kg CD34+ cells are infused after high-dose therapy, particularly with GM-CFC less than 1
133                                          For high-dose therapy patients, -17(p13) and t(4;14) have cl
134                      Three to 7 months after high-dose therapy, patients received a series of monthly
135 , symptomatic myeloma and not candidates for high-dose therapy plus HSCT, and an Eastern Cooperative
136 d 3-fold lower than the mean AD for low- and high-dose therapy, respectively.
137 mide-doxorubicin-vincristine-prednisone with high-dose therapy/stem-cell support prolongs remission a
138                       Long-term follow-up on high-dose therapy suggests a potential role for this mod
139  with less than 1 x 10(5)/kg GM-CFC received high-dose therapy supported by bone marrow collected aft
140                                        After high-dose therapy, the estimates of absorbed dose to the
141 on graft-versus-leukemia effects rather than high-dose therapy to eliminate malignant cells.
142               Mastectomy was performed after high-dose therapy to evaluate pathologic response to tre
143 a, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabin
144 ries of induction regimens and two cycles of high-dose therapy ("Total Therapy").
145 lmonary metastases 3 months after completing high-dose therapy, underwent complete resection of lung
146 isease evident on neuroimaging then received high-dose therapy using carmustine, etoposide, cytarabin
147 assessments supported the superiority of the high-dose therapy vs placebo.
148 ine and taxane therapy; cisplatin as part of high-dose therapy was allowed.
149 e use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase
150       The protective effect of short-course, high-dose therapy was stronger in households with 3 or m
151                     Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respe
152 esult, the trial was stopped and patients on high-dose therapy were crossed over to low-dose therapy.
153 py with anthracyclines and taxanes and prior high-dose therapy, were allowed.
154 n an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution.
155         This review evaluates the results of high dose therapy with stem cell reconstitution used to
156                                              High-dose therapy with allogeneic hematopoietic cell tra
157                                              High-dose therapy with autologous and allogeneic bone ma
158 ates that breast cancer patients who receive high-dose therapy with autologous CD34(+) marrow support
159 (32%) had progressive disease after previous high-dose therapy with autologous HCT.
160 nting paraprotein, in 550 patients receiving high-dose therapy with autologous hematopoietic cell tra
161                    Some subjects who receive high-dose therapy with autologous hematopoietic progenit
162                                              High-dose therapy with autologous hematopoietic progenit
163                                              High-dose therapy with autologous peripheral blood stem
164                       The upper age limit of high-dose therapy with autologous progenitor-cell and/ o
165                      Seven patients received high-dose therapy with autologous stem cell support, 3 o
166           Induction chemotherapy followed by high-dose therapy with autologous stem cell transplant a
167                                              High-dose therapy with autologous stem cell transplantat
168                              Early trials of high-dose therapy with autologous stem cell transplantat
169                                              High-dose therapy with autologous stem-cell rescue is an
170 ho are eligible for and those ineligible for high-dose therapy with autologous stem-cell transplantat
171                                              High-dose therapy with autologous stem-cell transplantat
172                                              High-dose therapy with melphalan 200 mg/m(2) is feasible
173                                              High-dose therapy with melphalan can prolong survival am
174 curs in patients undergoing long-term and/or high-dose therapy with nitrogen-containing bisphosphonat
175  less than 1 x 10(5)/kg GM-CFC, six received high-dose therapy with PBSC alone and five had delayed e
176  treatment of multiple myeloma, particularly high-dose therapy with peripheral blood stem cell transp
177  likely to relapse following three cycles of high-dose therapy with peripheral blood stem-cell rescue
178 egimen and consolidated with three cycles of high-dose therapy with peripheral blood stem-cell rescue
179 ients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue
180 Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have
181 s, administered alone or in combination, and high-dose therapy with stem cell transplant.
182                                              High-dose therapy with supporting autologous stem-cell t
183                                              High-dose therapy with tandem autologous stem-cell rescu
184 of the reductive pentosephosphate pathway by high-dose therapy with thiamine and the thiamine monopho
185  tandem high-dose, myeloablative treatments (high-dose therapy) with stem-cell rescue (HDT/SCR) in ra
186 efractory' conditions have been treated with high-dose therapy, with or without autologous stem cell
187                                              High-dose therapy, without or with stem cell transplanta
188 e myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do c

 
Page Top